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drug development, rather than following the adult indications, by matching an 
aggregated biological database of paediatric tumours with an aggregated drug 
pipeline. This is a new paradigm that should allow early evaluation of new drugs in 
children and adolescents.  
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Abstract 
An urgent need remains for new paediatric oncology drugs to cure children who die 
from cancer and to reduce drug-related sequelae in survivors. In 2007, the European 
Paediatric Regulation came into law requiring industry to create paediatric drug (all 
types of medicinal products) development programmes alongside those for adults.  
Unfortunately, paediatric drug development is still largely centred on adult conditions 
and not the mechanism of action (MoA)-based model, even though this would be 
more logical for childhood tumours as these have much fewer non-synonymous 
coding mutations than adult malignancies. Recent large-scale sequencing by ICGC 
(International Genome Consortium) and PCGP (Pediatric Cancer Genome Project) 
has further shown that the genetic and epigenetic repertoire of driver mutations in 
specific childhood malignancies differs from more common adult-type malignancies.  
To bring about much needed change, a Paediatric Platform, ACCELERATE, was 
suggested in 2013 by the Cancer Drug Development Forum (CDDF), Innovative 
Therapies for Children with Cancer (ITCC), the European Network for Cancer 
Research in Children and Adolescents (ENCCA) and the European Society for 
Paediatric Oncology (SIOPE). The Platform, comprising multiple stakeholders in 
paediatric oncology, has three Working Groups (WG), one with responsibility for 
promoting and developing high-quality MoA-informed paediatric drug development 
programmes, including specific measures for adolescents. Key is the establishment 
of a freely accessible aggregated database of paediatric biological tumour drug 
targets to be aligned with an aggregated pipeline of drugs. This will enable 
prioritization and conduct of early-phase clinical paediatric trials to evaluate these 
drugs against promising therapeutic targets and to generate clinical paediatric 
efficacy and safety data in an accelerated time-frame. Through this work, the 
Platform seeks to ensure that potentially effective drugs, where the MoA is known 
and thought to be relevant to paediatric malignancies, are evaluated in early phase 
clinical trials, and that this approach to generate pre-clinical and clinical data is 
systematically pursued by academia, sponsors, industry and regulatory bodies to 
bring new paediatric oncology drugs to front-line therapy more rapidly.  
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Introduction 
Survival rates for children with cancer increased from 20% to 80% between the 
1960s and 1990s (Craft and Pearson 1990, Rössig 2013).  Disappointingly this 
progress has not continued and improvements have plateaued over the last 25 years 
optimising conventional therapies as undertaken in high-income countries (Pritchard-
Jones K, 2013), with children and young people not benefiting from the current 
expansion in targeted, mechanism of action (MoA)-based therapies in adults.  
Twenty percent of children with cancer still die from this disease in Europe and North 
America, with the outcomes for high-risk neuroblastoma, high-risk medulloblastoma, 
metastatic sarcoma, bone tumours, high-risk ependymoma, and high-grade glioma 
remain very poor.  Furthermore, 40% of survivors live with disabling sequelae 
through adulthood (Vassal 2013a).  In part this lack of progress can be attributed to 
sub-optimal methods of paediatric oncology drug development, which largely 
continue to be driven by drug development for adult cancers. There is also an 
unjustified adherence to the separation of adults and minors in clinical trials, despite 
the known maturation of hepatic and renal systems in older children, with minors at 
times being excluded from entering “adult” early phase cancer studies, although this 
has no physiological basis. Additionally, until recently, a ‘silo’ method of working was 
prevalent amongst the many different groups in the field. However, in all three areas 
change is manifest.   
 
A force for change has been the European Paediatric Medicine Regulation EC No. 
1901/2006 which requires an agreed Paediatric Investigation Plan (PIP) (EMA 2006) 
to provide data supporting paediatric usage as part of each new adult drug 
development plan. However, where adult and paediatric diseases (conditions) are not 
the same, the Regulation allows for waivers of paediatric studies if the disease that 
the drug is being developed for only occurs in adults.  
 
To accelerate progress, a Paediatric Oncology Platform, ACCELERATE, comprising 
three Working Groups (WG) was formed in 2013 (Vassal 2015). This paper reports 
on progress made by one WG in MoA-driven drug development. This represents a 
paradigm shift that will benefit children and adolescents.  
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Context/landscape 
Paediatric Medicine Regulation and paediatric oncology drug development in Europe 
Before the European Paediatric Medicine Regulation No EC 1901/2006 (the 
Regulation), clinical evaluation of new agents for paediatric and adolescent 
malignancies was often absent and by necessity drugs were most often used off-
label.  The Regulation provided obligations and incentives through completing PIPs 
and in conjunction with the legislation on orphan drugs aimed to facilitate a much-
needed change to drive paediatric drug development forward.  It sought to ensure 
that such medicines were developed with high-quality, ethical research in children, 
without subjecting them to unnecessary clinical trials, but balancing this with the 
reality and hazards of off-label use, and at the same time ensuring no delays to adult 
drug development.  Thus PIPs became the means by which paediatric drug 
development was planned based on proposals by pharmaceutical companies, 
optimal collaboration with academic networks, and agreement by the Paediatric 
Committee of the EMA (PDCO).  
 
Pharmaceutical companies developing new medicines are legally bound to comply 
with agreed PIPs to submit the marketing authorisation (MA), but may request a 
waiver which obviates this requirement.  Waivers, if requested, are to be granted 
because (i) the adult condition on the proposed drug label does not occur in children 
(e.g., breast cancer); (ii) the drug would likely be unsafe or ineffective in children; (iii) 
there is no significant therapeutic benefit above existing paediatric treatment. The 
marketing authorisation of everolimus for subependymal giant cell astrocytoma is a 
prototype for successful MoA driven drug development in paediatric oncology.  Whilst 
the Regulation has brought positive change and advances, the waiver mechanism 
means that with over 60% of 89 potentially valuable anticancer drugs granted a 
waiver (Vassal and Pearson Personal Communication 2015), there are still few 
paediatric trials and only between 9–15% of all oncology agents have ongoing 
paediatric studies (Vassal 2013b, FDA Pediatric Oncology Subcommittee of ODAC, 
November, 2013).  Thus many children with cancer continue to have limited options 
and no access to new therapies.  
 
Implementation of MoA drug development for children with cancer 7-1-16 FINAL 
 
Although the Regulation already includes the possibility of agreeing PIPs for biology-
driven, paediatric development within or outside of that for adults, in truth paediatric 
drug development is still largely driven by that for adults.  From 2008–2012 over 470 
PIPs were agreed covering all paediatric therapeutic areas, with 52 PIPs for 
malignancies being one of the largest areas, but only a few PIPs for cancers that 
specifically occur in children and adolescents; and only a few were completed by the 
time of the EMA’s 5-year interim report on the Regulation (EMA 2013).  
 
The Paediatric Platform - ACCELERATE 
In 2013, the Cancer Drug Development Forum (CDDF), Innovative Therapies for 
Children with Cancer (ITCC), the European Network for Cancer Research in Children 
and Adolescents (ENCCA) and the European Society for Paediatric Oncology 
(SIOPE) suggested creating a Paediatric Oncology Platform comprising 
representative stakeholders involved in the care of children with cancer – academia, 
industry, regulatory authorities and parent and patient advocates (Vassal 2015).  Its 
WGs address key aspects of paediatric oncology drug development: (i) New 
strategies for improved development of oncology drugs for children and adolescents 
including MoA, biology-driven drug development; (ii): New incentives for specific 
paediatric drug development and repositioning; (iii) Implementation of long-term 
follow up measures for children and adolescents receiving new anticancer drugs. 
Each WG includes representatives from each stakeholder group, but is led by a 
member with the relevant expertise for the work stream.  
 
MoA biology-driven development 
First principles 
Core to this approach is discovery and understanding of the molecular pathways, 
biology and key drivers of paediatric malignancies focussing on gene/pathway 
aberrations that demonstrate a proof of “tumour dependence”, combined with 
detailed biological insight of a drug’s MoA. The paediatric oncology research 
community through extensive collaboration worldwide has been at the forefront of 
exploiting next-generation sequencing technologies to gain better insight into tumour 
biology (Zhang 2013, Hovestadt 2014, Kool 2014, Buczkowicz 2014, Taylor 2014, 
Wu 2014). Furthermore, it is critically important to realize that the average number of 
non-synonymous coding mutations in childhood tumours is on average about a 
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hundred fold lower than in adult malignancies.  This means that the likelihood of 
correctly identifying the “Achilles Heel” of the tumour for targeted therapies is much 
higher thus comprising a much more promising and clean target population for MoA-
based drugs to actually work.  With this knowledge, one can take a more systematic 
approach matching drugs with an identified MoA to a particular disease or across 
different diseases based on biology.  Pre-clinical research varies with different 
tumour types, and may be limited by availability of tumour samples and/or relevant 
pre-clinical tumour models; this remains a particular challenge for paediatric cancers. 
The proposed MoA approach aims to identify appropriate paediatric patient 
populations to which MoA-driven drug development is applicable.  
 
Broadly, paediatric oncology drugs can be categorised as: i) those for diseases 
occurring in adults and children, e.g., gliomas and certain haematological 
malignancies; ii) those targeting a MoA relevant/common to both the intended adult 
cancer and a distinct/different paediatric malignancy, such as BRAF, e.g., melanoma 
in adults; high and low grade gliomas and histiocytosis in children, or one different in 
terms of molecular alteration, such as anaplastic lymphoma kinase [ALK] alterations 
in neuroblastoma rather than non small cell lung cancer; iii) those against targets 
specific to, or predominant in, paediatric malignancies, e.g., MYCN, which has not 
yet been developed as a relevant target in adult cancers. Other targets in this last 
group are currently being identified from paediatric pan-cancer analyses of next-
generation sequencing programmes. 
 
Practicalities of a MoA model 
The key elements of a MoA approach are: i) an aggregated database which 
establishes the incidence and prognostic relevance of tumour targets in paediatric 
malignancies; ii) appropriate selection of drugs; iii) drug prioritisation; iv) specific pre-
clinical and clinical studies (early and late phase clinical trials) (Figure 1). 
 
An iterative, life-cycle approach should be adopted for MoA-driven drug development 
and can be reflected in PIP modifications, with the direction of drug development 
continually reviewed following evolution of the data and applicable science.  The 
Paediatric Committee is not at liberty to require a MoA-driven development for a 
childhood cancer that is different from the cancer targeted in adults, or to require PIP 
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modifications, but has agreed to a number of such proposals by pharmaceutical 
companies.  Currently, PIPs are relatively ‘fixed’ at the time of their agreement 
though some include obligations on the part of the PIP addressee (mostly industry) to 
go back for further review.  A systematic life-cycle approach would thus have many 
advantages, and would be important particularly when multiple companies generate 
data on the same target and/or in the same class of drug.  
 
(i) Aggregated database of tumour targets 
Central to this approach is an aggregated and publicly available database of the 
critical pathways / drivers in different paediatric and adolescent malignancies, 
enabling matching of the MoA to a specific disease.  The incidence/prognostic 
relevance in individual malignancies and across cancer types should be included in 
the database and evidence supporting the strength of the target as a cancer driver.  
Detailed molecular profiling of tumours both at presentation and relapse will provide 
information. The incidence of actionable target mutations is the most easily obtained 
information; determination of the functional relevance of identified targets for tumour 
cell survival and the relevance of complicated tumour-host interactions is a more 
challenging task.  
 
The aggregated database will define the non-clinical rationale for choosing a 
paediatric MoA-informed approach.  Drug selection is based on the presence and 
prioritisation of molecular targets as key drivers, altering clinical outcomes of 
paediatric malignancies.  The database will be used to develop predictive pre-clinical 
models that recapitulate clinical features of the paediatric tumours.  Drug 
development will be based on targets across tumour types.  Due to the distribution of 
tumour targets, some will predominate in one disease and development of drugs may 
in practice tend to be led by that tumour type.  However, practice should evolve so 
that the target rather than the histological tumour type defines the medicine used. 
Such a database will also be crucial when considering treatment combinations. 
 
(ii) Selection of drugs 
The goal is to match, as early as possible, the tumour biology, including interaction 
with the host environment, with drugs already in the development process; this 
requires alignment of an aggregated pipeline of drugs with an aggregated database 
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of paediatric tumour targets.  Selection of drugs should be based on knowledge of 
the molecular pathways relevant to paediatric malignancies, not on the wording of the 
adult disease or condition.  
 
(iii) Drug prioritisation 
Prioritised drugs from a co-ordinated pipeline of agents should target strong drivers in 
paediatric malignancies where there are unmet needs.  Prioritisation could be 
informed by structured overviews of the pre-clinical biological knowledge in paediatric 
malignancies and of the gene/pathway aberrations matching the MoA of the drugs.  
Drugs which “fit” with paediatric biological tumour targets will then undergo detailed 
evaluation comprising a review of treatment strategies, regulatory incentives and 
obligations, molecular mapping within the oncology portfolio and proof-of-concept 
studies in relevant paediatric preclinical models.  This will enable the best-informed 
selection and timing of medicines for studies and avoid duplication.  
 
Novel drugs with a similar MoA can then be “compared” in a non-competitive space, 
such that precious resources are not wasted, and paediatric patients are not enrolled 
on sub-optimal clinical studies unlikely to benefit them.  However, this process 
involving multiple stakeholders will involve significant challenges. Accordingly, this 
ability to compare mechanisms, efficacy and toxicity profiles, and match rare children 
to the best available experimental therapy requires further discussion with academia, 
pharmaceutical industry partners as well as with regulatory authorities. 
 
(iv) Studies 
Pre-clinical studies 
In view of the large number of compounds of the same class available from different 
pharmaceutical companies, pre-clinical proof-of-concept research is advocated to 
adequately prioritize them through pre-competitive multi-company integration. This 
should ideally include non-clinical safety evaluation, dosing schedule determination, 
combination testing and mechanism of resistance-analysis, as well as cross-
company comparison of non-clinical efficacy, based on molecular mechanisms (for 
instance ALK translocations versus mutations). 
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Non-clinical studies exploring the toxicities of these targeted therapies in juvenile 
animals should enable detection of their potential negative impact on the function or 
development of major organs in children.  Key issues are the secondary 
pharmacological properties of these drugs, which are not always well understood.  
These studies also enable the detection of unexpected or exacerbated toxicities 
when compared with adult animals. Key issues are higher exposure levels linked to 
immature pharmacokinetics in the younger populations (often metabolic or renal 
clearances) or toxicities affecting immature organs. 
 
Selection of the right drug(s) for clinical evaluation is needed, for which factors such 
as safety and posology are important considerations.  
  
Clinical studies - early phase clinical trials 
Early phase (including first-in-child) clinical trials in a MoA approach should have a 
clinically relevant, biology-driven hypothesis, be feasible and encompass Phase I 
(dose-finding and toxicity) and II (proof-of-concept) elements and include expansion 
cohorts as necessary.  The objective is to efficiently and rapidly determine the 
paediatric recommended Phase II dose (RP2D), toxicity, pharmacological profile and 
activity signals aiming for optimal biological dose and not MTD.  As therapeutic intent 
is key to the design of such studies in children, appropriate stopping rules, a shift 
towards more effective therapies, early introduction of combination therapy and 
innovative designs should be considered.  
  
An early phase clinical study should be initiated once there is a strong biological 
rationale for a drug targeting a molecular pathway driving the malignancy and as 
soon as a feasible trial can be designed and deliverable within an acceptable 
timescale (two years).  As a rule, as soon as the adult RP2D has been determined 
(early phase), paediatric studies should commence as this time point is supported in 
the regulation for PIP applications.  There is a role for very early evaluation of some 
drugs in children if there is a strong biological rationale, even before therapeutic trials 
in adults.  
 
It is recommended that any early phase paediatric clinical study with a new medicine 
should be scientifically optimised to progress drug development and disease 
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knowledge.  Regulators are involved in clinical trial authorisation and should 
participate in scientific dialogue because of added value from their scientific 
experience across medicine pipelines.  Lack of agreed PIPs does not prevent early 
clinical trials in children, but discussions of a PIP or scientific advice should take 
place with regulators to avoid trials that are unnecessary or not useful.  Evolving data 
should inform later stages of drug development. To develop drugs for paediatric 
indications that are unrelated or “outside” an adult condition for which there is a 
medicine authorised or in development, a PIP may still be proposed and agreed, 
thereby giving companies the potential for access to the reward related to 
compliance with progressing and completing such a programme.  
 
Experience and evidence have shown that unacceptable toxicity is rarely seen in 
paediatric studies at 100% adult RP2D (Paoletti, 2013). It is therefore now proposed 
to start at 100% of exposure at the adult RP2D adjusted for body surface area 
(unless there is a good reason not to do so) and to predict the exposure from 
modelling physiological and adult data.  Special attention should be paid to anticipate 
more severe toxicity in very young children with immature organ function (in 
particular those less than 2 to 3 years of age).  Mixed criteria for toxicity and efficacy 
(including the optimal biological dose) should be employed to establish the RP2D.  
Ideally, the selected dose will be based on determining on-target activity 
measurements of the compound or non-maximum tolerated dose optimization 
strategies. Multi-arm designs (“matrix” trials) (Middleton, 2015) should be used in 
early and later paediatric trials, where feasible. Predictive biomarkers to aid patient 
selection are important in some studies when there is an actionable mutation, 
however they may not be available nor validated when starting a first-in-child trial. In 
addition tumour clonal evolution and tumour heterogeneity should be considered.  
 
There should be a collection of (ideally, fresh frozen) tumour material at the time of 
enrolment in a study and/or at relapse in order to run biologically well informed trials 
with knowledge of the current biological status of the tumour and so not rely on 
archived material, which may lead to incorrect conclusions if the tumour has 
developed new genetic aberrations over time; a phenomenon known to be true in an 
increasing number of tumour types including neuroblastoma and medulloblastoma 
(Schleiermacher, 2014; Hill, 2015). It is also critical that this tissue is assessed in 
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comparison with biopsies obtained at diagnosis, to address the issue of tumour 
heterogeneity/clonal evolution. Although sequential tumour samples are of significant 
value, they may not always be feasible.  The role of liquid biopsies, e.g., circulating 
DNA obtained from blood samples, should be considered as well; the use of these 
could also reduce the trial-related burden for the patients.  Furthermore, studies of 
these tumour samples will reveal resistance mechanisms and provide a rational basis 
for combination therapies.  
 
Consultation on design of early and subsequent clinical trials should be timely and 
detailed, and involve contributions from academia, industry, regulators, older 
children/adolescents and patient/parent advocates and representatives.  Academia 
should participate from the outset, as pivotal information regarding adaptation to 
improving outcomes in paediatric malignancies (such as addressed in a PIP), as well 
as expert advice on feasible trial designs, can be obtained through this source.  
Scientific advice (as part of a PIP or as a specific procedure) can also be obtained 
from regulators based on their extensive review of medicines and scientific 
experience across pipelines.  In order to facilitate planning of regulatory discussions 
in initiating clinical trials, across territories, efforts should be made to engage and 
align major regulatory agencies (e.g., EMA and FDA) as early as possible.  
 
Clinical studies – later phase clinical trials 
The aim is to take forward drugs from early phase trials if supported by data, whilst 
postponing or discontinuing paediatric development of inactive drugs.  With results 
from appropriately designed and conducted early phase clinical studies no further 
evaluation of some drugs will be required, whilst others should progress to evaluation 
of safety and efficacy, such as in randomised parallel-group or multi-arm, multi-stage 
later-phase clinical studies.  
 
Ultimately, larger late-phase clinical studies will be required to demonstrate efficacy 
in the paediatric population.  However, these studies should not be expected to be 
identical to those performed in adults.  The number of paediatric/teenage patients 
with given target(s)/ disease(s) available for inclusion in such studies within a 
reasonable time frame must be borne in mind, and trial designs must be 
reconsidered and optimised for these rare population subgroups in the era of MoA- 
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based drug development.  Randomized clinical trials are comparative in principle: the 
primary question, ‘‘can we identify person/people for whom this is the right 
treatment/drug?’’ is fundamentally different from asking which treatment performs 
better or best in the population overall and the latter, classical phase III approach 
may not answer the primary question.  
 
Application of a MoA approach in adolescents 
Historically patients <18 years have been excluded from adult clinical studies, even 
when the disease under investigation and the MoA of the drug under study would 
suggest this to be unnecessary.  For example, although rare, adolescents may 
develop metastatic melanoma with a very poor prognosis (Berk 2010) and should not 
be refused access to trials with innovative compounds being developed for adults.  
There are currently four drugs with agreed PIPs for melanoma patients aged 12-18 
years with 5-7-year timelines and study-end-dates ranging from 2017-2019, even 
though the drugs are authorised for their adult counterparts.  Recruitment to most of 
the melanoma trials conducted for adolescents is slow, chiefly because of the rarity 
of the disease in this age group when considered in isolation, the off-label usage of 
these experimental drugs available to adults, and the rapid evolution of standards of 
care.  In the future, it would seem sensible to include adolescents (from the age of 12 
years) in early phase clinical studies and large pivotal trials currently only open to 
adult patients (18 years and above).  They would still be cared for clinically by 
paediatric oncologists with age-specific expertise, even though the involvement of 
both adult and paediatric health professional as investigators might add complexity to 
such a trial.  This approach would also be appropriate for other rare cancers and 
more generally in the teenage group of patients.    
 
An example of MoA driven drug development 
Inhibitors of BRAF have shown clinical value in the treatment of malignant 
melanomas.  In addition BRAFV600 has been demonstrated to be an oncogenic 
driver in paediatric gliomas (Bautista 2014). There are two early-phase paediatric 
clinical studies of BRAF inhibitors – vemurafenib and dabrafenib – currently taking 
place (Bautista 2014, Kieran 2015).  The development of dabrafenib is considered a 
paradigm for the MoA biology-driven approach by paediatric oncologists where the 
early phase clinical trial has focussed on common paediatric tumours, with an unmet 
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need for new drugs, where BRAF mutations are thought to play a major role in the 
pathogenesis.  Complete and partial responses are being seen in BRAF mutated 
high-grade and low-grade gliomas (Keiran 2015), Although drugs targeting this 
mutation are relevant only for a subpopulation of patients, the disease represents a 
high unmet medical need and a difficult to treat disease in all patients. 
 
Benefits and Challenges 
A MoA biology-driven approach to drug development for paediatric cancers would 
support the objectives of all stakeholders by giving patients better access to 
potentially effective treatment underpinned by sound scientific knowledge and data.  
A greater number of potentially effective drugs would be evaluated more rapidly in 
paediatric early phase clinical studies and have the opportunity to reach front-line 
therapy more rapidly. For adolescents, integration with “adult” studies could mean 
better access to a wider range of therapeutic options earlier in treatment.  
 
For companies developing drugs, this approach would provide a cooperative working 
model with advantages for all through shorter and more effective trials with a robust 
scientific approach, and better, faster recruitment of patients, enabling drugs to go 
from bench to bedside more quickly. On the regulatory side this may make for a 
clearer and more straightforward path to successful label updates.  
 
To reap the benefits of a MoA approach, certain challenges must be overcome.  The 
“rules of engagement” need to be defined; for example, that work in the pre-
competitive space requires companies to share sensitive information, and that not all 
drugs will be studied at a phase III level and may be deprioritized, needs to be widely 
appreciated.  Currently, no paediatric medicines legislation in the EU or elsewhere in 
the world has been substantially modernised, this has however been discussed by 
US legislators (Young 2015). In the EU, introducing such changes would facilitate 
prioritising the development of relevant oncology medicines for children by the 
Paediatric Committee.  Finally there is a need for an open, public prioritization forum 
where all parties would regularly exchange information so as to allow for a timely 
updating of the life cycle of each drug/class of drug/disease area.   
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Conclusions 
This strategy for MoA, biology-driven, paediatric oncology drug development will 
accelerate drug development and will enact groundbreaking changes in the delivery 
of precision medicines to children. The paradigm is to conduct early-phase paediatric 
studies, which efficiently evaluate drugs against targets identified in an aggregated 
database of paediatric tumour targets. This database has already been initiated by 
the ITCC.  A number of PIPs have already been agreed on the basis of a proposed 
MoA approach. This will ultimately result in new drugs being introduced rapidly into 
front-line therapy, thereby increasing survival and reducing sequelae of therapy for 
children and young people with cancer.  
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